Reassuring organic growth for undervalued ASX share
Efficiency gains are starting to make their mark.
Mentioned: Sonic Healthcare Ltd (SHL)
Sonic Healthcare (ASX: SHL) reaffirms fiscal 2027 underlying EBITDA guidance of $1.95 billion to $2.03 billion at constant currency. In the four months to October, organic revenue growth was 4.4%, led by Australia, while Switzerland was the laggard.
Why it matters: Momentum remains steady in Australia, where Sonic generates 20% of group revenue from pathology and 10% from radiology. The former’s 6% organic growth year-to-date is above the 5% delivered in fiscal 2026, and the 8% for the latter is also a little higher.
- Even more encouraging is the performance overseas. US organic revenue is up 4% year-to-date, compared with 2% in fiscal 2026. This provides some top-line revenue help, as operating restructuring and efficiency improvements continue for a unit that accounts for almost 20% of group revenue.
- Organic growth in Germany (25% of group revenue) and the UK (8%) are also up 4% year-to-date, maintaining their recent momentum. In contrast, the mere 1% organic growth for Switzerland reflects adverse regulatory changes reducing fees, stunting around 10% of group revenue.
The bottom line: We retain our $27 fair value estimate for Sonic Healthcare, as our operating earnings forecasts are unchanged. Our fiscal 2027 EBITDA forecast of $1,945 million remains at the low end of the guidance range, reflecting unfavorable currency movements.
- However, underlying revenue trends are reassuring and testify to Sonic’s defensive appeal. This is at a time when significant “self-help” initiatives are underway to improve operations in the US, while synergies are being extracted from recent acquisitions in Germany and Switzerland.
- Investors appear reluctant to price in the potential longer-term margin uplift from these initiatives, with shares in the narrow moat-rated group trading 24% below our intrinsic assessment. But we continue to project EBITDA margin recovering to 19.2% midcycle, from 17.6% currently.
Sonic Healthcare’s reassuring revenue growth
Sonic Healthcare provides laboratory medicine/pathology and diagnostic imaging radiology. It is the third-largest private provider of laboratory medicine globally, behind Quest Diagnostics and Labcorp. Strategy focuses on being a low-cost provider and gaining cost advantage over competitors through scale. This has mostly been pursued through acquisitions, buying smaller operators to expand its market share in geographies where it operates. The firm emphasizes medical leadership, recognizing referring doctors as the primary customer, focusing on improving their experience and efficiency.
Sonic has grown via acquisitions in multiple regions, first in its home market Australia, where it’s the largest operator with over 40% of the pathology market and 10% of the diagnostic imaging market. Pathology operates under a hub-and-spoke model, whereby multiple collection facilities feeding centralized laboratories, acquisition synergies procurement, and IT integrations mean most acquisitions are accretive.
The same roll-up strategy is used internationally, and Sonic is now the largest private pathology provider in Germany, the UK, and Switzerland, and a major provider in Belgium, New Zealand, and the US. In most international markets, pathology providers face similar pressures, with government reimbursements lagging testing costs. We see consolidation in Europe and the US as likely, as smaller operators are eventually outcompeted by larger providers with lower costs per test.
Sonic is navigating lower testing volumes since the end of the covid-19 pandemic, and higher labor costs fueled in part by postpandemic inflation. Profits peaked at AUD 1.5 billion in fiscal 2022 and more than halved to AUD 0.5 billion in fiscal 2024, similar to fiscal 2018 levels. This, alongside concerns about potential German healthcare and reimbursement reform leading to cuts to payments for pathology tests, has weighed on the shares.
We forecast group profitability improving, driven by rationalization of its US anatomical pathology operations, increasing testing volumes in the UK from its new Watford laboratory, and cost savings from the integration of the acquisition of LADR in Germany.
Bulls say
- The business is defensive, providing an essential service, not tied to economic cycles.
- Sonic has large market shares in most geographies it operates, including being the largest pathology provider in Australia and Europe.
- Growth is leveraged to long-term tailwinds from an aging population and increasing levels of testing per person.
Bears say
- Earnings are tied to government policy and funding, and changes in policy to government rebates for laboratory medicine and imaging.
- Growth has been in part fueled by acquisitions; improvements in profitability are tied to unlocking synergies and scale benefits from mergers.
- Returns on invested capital are only modestly above WACC, suggesting the value of any moat is modest.
